PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
Author(s) -
Paula Ghaneh,
Robert N. Hanson,
Andrew Titman,
Gill Lancaster,
Catrin Plumpton,
Huw LloydWilliams,
Seow Tien Yeo,
Rhian Tudor Edwards,
Colin Johnson,
Mohammad Abu Hilal,
Antony Higginson,
Thomas Armstrong,
Andrew M. Smith,
Andrew Scarsbrook,
Colin J. McKay,
Ross Carter,
Robert P. Sutcliffe,
S. Bramhall,
Hemant M. Kocher,
David Cunningham,
Stephen P. Pereira,
Brian R Davidson,
David Chang,
Saboor Khan,
Ian Zealley,
Debashis Sarker,
Bilal Al Sarireh,
Richard Charnley,
Dileep N. Lobo,
M. Nicolson,
Christopher Halloran,
Michael Raraty,
Robert Sutton,
Sobhan Vinjamuri,
Jonathan Evans,
Fiona Campbell,
Jonathan J Deeks,
Bal Sanghera,
WaiLup Wong,
John P. Neoptolemos
Publication year - 2018
Publication title -
health technology assessment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.426
H-Index - 126
eISSN - 2046-4924
pISSN - 1366-5278
DOI - 10.3310/hta22070
Subject(s) - medicine , positron emission tomography , radiology , pancreatic cancer , malignancy , pancreatitis , pet ct , prospective cohort study , nuclear medicine , cancer
Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom